These data proposed that PGC-1α modifies ROS in MM and that suppression of augmented PGC-1α after chemotherapy causes a further augment of ROS by reducing the antioxidant component, finally increasing the antineoplastic action of BTZ [49]. Here, PPARGC1A is linked to Miyoshi myopathy.